Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

IDEAYA Biosciences Inc IDYA

Healthcare Biotechnology
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates are darovasertib (IDE196), IDE397, IDE161 and GSK101 (Pol Theta Helicase). IDE196, a small molecule protein kinase C (PKC), inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397, is its small molecule methionine adenosyltransferase 2a (MAT2A), inhibitor. IDE161, is its small molecule poly (ADP-ribose) glycohydrolase (PARG), inhibitor. IDE196 is its clinical-stage PKC inhibitor that the Company is evaluating as a synthetic lethal combination therapy. IDE397, a MAT2A inhibitor for patients with solid tumors having MTAP deletions. IDE161 is its clinical-stage, potent and selective small molecule inhibitor of PARG for patients having tumors with defined biomarkers based on genetic mutations and/or molecular signatures.


NDAQ:IDYA - Post by User

IDEAYA Biosciences Inc
Bullboard Posts
Next >>
User Avatar Image
(4)
•••
  • AviseAnalyticsX
Post by AviseAnalyticson Jan 26, 2022 8:12am
116 Views
Post# 34361352

EMERGING PARADIGMS IN TREATMENT OF MELANOMA!

EMERGING PARADIGMS IN TREATMENT OF MELANOMA!$IDYA $NKTR $MGNX $CTMX $ALKS

Melanoma, a form of skin cancer, accounts for about 1% of skin cancers but is responsible for over 7,650 deaths every year as per an estimate by the American Cancer Society, these numbers are steadily rising over the years with approximately 99,780 new melanomas diagnosis being made each year. 

However, the prohibitive cost of treatment may prove challenging and affect the growth prospects to an extent. A number of clinical trials are underway in the melanoma treatment industry with companies introducing unique first-in-class treatment options, some of which are enumerated in our today's coverage. 

Read on to know more!

https://www.aviseanalytics.com/emerging-paradigms-in-treatment-of-melanoma/ 
 
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities